Triantafillidis JK, Zografos CG, Konstadoulakis MM, Papalois AE. Combination treatment of inflammatory bowel disease: Present status and future perspectives. World J Gastroenterol 2024; 30(15): 2068-2080 [PMID: 38681984 DOI: 10.3748/wjg.v30.i15.2068]
Corresponding Author of This Article
John K Triantafillidis, PhD, Honorary Associate Professor, Inflammatory Bowel Disease Unit, "Metropolitan General" Hospital, 264 Mesogeion Avenue, Holargos 15562, Attica, Greece. jktrian@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 21, 2024; 30(15): 2068-2080 Published online Apr 21, 2024. doi: 10.3748/wjg.v30.i15.2068
Combination treatment of inflammatory bowel disease: Present status and future perspectives
John K Triantafillidis, Constantinos G Zografos, Manousos M Konstadoulakis, Apostolos E Papalois
John K Triantafillidis, Inflammatory Bowel Disease Unit, "Metropolitan General" Hospital, Holargos 15562, Attica, Greece
John K Triantafillidis, Hellenic Society for Gastrointestinal Oncology, 354 Iera Odos, Chaidari 12461, Attica, Greece
Constantinos G Zografos, Manousos M Konstadoulakis, The 2nd Department of Surgery, University of Athens, School of Medicine, Aretaieion Hospital, Athens 11528, Greece
Apostolos E Papalois, Unit of Surgical Research and Training, The 2nd Department of Surgery, University of Athens, School of Medicine, Aretaieion Hospital, Athens 11528, Greece
Author contributions: Triantafillidis JK, Zografos CG, Konstadoulakis MM and Papalois AE, conceived and designed the analysis, collected the data, performed the analysis and wrote the paper.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: John K Triantafillidis, PhD, Honorary Associate Professor, Inflammatory Bowel Disease Unit, "Metropolitan General" Hospital, 264 Mesogeion Avenue, Holargos 15562, Attica, Greece. jktrian@gmail.com
Received: December 27, 2023 Peer-review started: December 28, 2023 First decision: January 16, 2024 Revised: February 20, 2024 Accepted: March 28, 2024 Article in press: March 28, 2024 Published online: April 21, 2024 Processing time: 113 Days and 17.4 Hours
Core Tip
Core Tip: During the last few years, the combination of two biological agents or a combination of a biological agent and another drug belonging to the category of so-called "small molecules" seems to be steadily gaining ground [dual biologic therapy (DBT)]. Even the combination of a biological agent with a drug belonging for example to the category of immunosuppressants is a therapeutic option that has been applied for several years [combination therapy (CT)]. Finally, in daily clinical practice, various combinations of so-called first-line drugs (mesalazine, corticosteroids, antibiotics, probiotics, etc.) are used with satisfactory results in most cases. DBT and CT currently find application in cases of patients resistant to treatment or patients with extraintestinal manifestations that do not respond satisfactorily to classical treatment. The existing data, although encouraging, are not sufficient in terms of the number of patients included so far. The safety of this emerging kind of treatment is another point of interest. Finally, there is a need to carry out more studies regarding this interesting field of research.
